Grant Skrepnek to Hepatitis C, Chronic
This is a "connection" page, showing publications Grant Skrepnek has written about Hepatitis C, Chronic.
Connection Strength
1.908
-
Hepatitis C Direct-Acting Antiviral Treatment Selection, Treatment Failure, and Use of Drug-Drug Interactions in a State Medicaid Program. J Manag Care Spec Pharm. 2019 Nov; 25(11):1261-1267.
Score: 0.651
-
Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost. J Am Pharm Assoc (2003). 2018 Sep - Oct; 58(5):485-491.
Score: 0.595
-
Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid. J Manag Care Spec Pharm. 2018 Jul; 24(7):664-676.
Score: 0.593
-
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007 Jun; 27(6):813-24.
Score: 0.069